Evaluation of Treatment Effects on Patients with Sleep-related Breathing Disorders and Epilepsy Comorbidity
By
Öztürk, Ü (Ozturk, Uzeyir) [1] ; Ak, AK (Ak, Aysin Kisabay) [2] ; Batum, M (Batum, Melike) [2] ; Yilmaz, K (Yilmaz, Kmet) [2]
(provided by Clarivate)
Source
JOURNAL OF TURKISH SLEEP MEDICINE-TURK UYKU TIBBI DERGISI
Volume
12
Issue
3
DOI
10.4274/jtsm.galenos.2025.16680
Published
SEP 2025
Indexed
2025-10-23
Document Type
Article
Abstract
Objective: Epilepsy and sleep-related breathing disorders (SBD) are among the most prevalent conditions in neurology. This study aimed to compare sleep parameters in patients with primary snoring-epilepsy (PrS-E) and severe obstructive sleep apnea syndrome-epilepsy (OSAS-E). Additionally, the study sought to assess the mutual effects of treatments administered in each clinical area on the other. Materials and Methods: Patients who were subjected to follow-up in the sleep laboratory and epilepsy outpatient clinic between 2006 and 2022 were analysed retrospectively, following approval from ethics committe. The demographic data, medical history, characteristics of epileptic seizures, electroencephalograms (EEGs) and antiseizure drugs (ASD) before and after SBD treatment were compared. The effect on sleep structure and respiratory issues of lowering the dose of ASD after SBD treatment was also assessed. Results: The study included 28 patients with PrS-E and 28 patients with severe OSAS-E. Focal onset impaired awareness focal to bilateral tonic-clonic seizures were found to be more prevalent in both groups. Following treatment for SBD, there was a decline in seizure severity and frequency, a resolution of EEG pathologies, or a decrease ASDs in both groups. The reduction in ASDs and treatment for SBD resulted in an improvement in sleep structure, a reduction in body mass index, snoring, and Epworth Sleepiness Scale scores. Conclusion: Treating SBDs can lead to a reduction in the dosage of ASD, improved sleep structure, and decreased snoring. This study demonstrated mutual benefits in the management of both epilepsy and SBDs. SBD symptoms should be investigated in epilepsy patients, and the presence of epileptic seizures should be considered in patients with SBD.
Keywords
Author Keywords
Obstructive sleep apnea syndrome primary snoring epilepsy antiepileptic drug
Prognostic factors in patients with cerebral sinus venous thrombosis presenting with hemorrhage and papilledema
By
Saritas, AS (Saritas, Aysegul Seyma) [1] ; Batum, M (Batum, Melike) [1] ; Ataç, C (Atac, Ceyla) [2] ; Öztürk, U (Ozturk, Uzeyir) [1] ; Yilmaz, H (Yilmaz, Hikmet) [1] ; Mavioglu, H (Mavioglu, Hatice) [3] ; Selçuki, D (Selcuki, Deniz) [3] ; Ak, AK (Ak, Aysin Kisabay) [1]
(provided by Clarivate)
Source
CLINICAL NEUROLOGY AND NEUROSURGERY
Volume
234
DOI
10.1016/j.clineuro.2023.108013
Article Number
108013
Published
NOV 2023
Early Access
OCT 2023
Indexed
2023-11-26
Document Type
Article
Jump to
Abstract
Objective: The thromboinflammatory process is considered to play a role in the pathogenesis and prognosis of cerebral sinus vein thrombosis (CSVT). The purpose of the study was to compare the thromboinflammatory parameters between individuals with CSVT and healty controls. Additionally, the study sought to compare these parameters among CSVT subgroups with and without haemorrhage, as well as with and without papilledema. Furthermore, the investigation also aimed to identify which parameters had a more significant impact on the risk of hemorrhage and the development of papilledema in CSVT.Methods: Thromboinflammatory parameters were compared retrospectively between the CSVT group of 88 patients and 80 age- and sex-matched healthy controls, and in the CSVT subgroups with (n = 35) /without hemorrhage (n = 53) and with (n = 52) /without papilledema (n = 36) after ethics committee approval. In both groups, parameters contributing to the risk of hemorrhage and papilledema development were determined by univariate and multivariate analyses.Results: Regarding the risk of hemorrhage in CSVT patients, the most significant factors included hematocrit of <30.2 (%), mean platelet volume of <= 8.9 fL, neutrophil count of >5600, and hsCRP of >9 mg/L. Regarding the risk of papilledema development, the most important risk factors were age of <= 49, presence of vomiting, presence of blurred vision, HDL of >47 mg/dL, and D-dimer of >178 ng/mL.Conclusion: It was suggested that evaluating serum thromboinflammatory parameters, as well as demographic characteristics and neurological examination findings, had a critical role regarding prognosis and predictive factors in CSVT.
Keywords
Author Keywords
Cerebral sinus vein thrombosis Inflammation Thromboinflammatory parameters